Calcimimetics and outcomes in CKD

Kidney International Supplements

Volumn 3, Issue 5, 2013, Pages 431-435

  Drüeke, Tilman B ^a  

^a INSERM   (France)

Author keywords

Calcimimetics; CKD; CKD MBD; Outcomes; Vascular calcification

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; CINACALCET;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EXPERIMENTAL STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; VASCULAR TISSUE;

EID: 84896733418     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2013.90     Document Type: Review

References (38)

1. Riccardi D, Kemp PJ. The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, and disease. Annu Rev Physiol 2012; 74: 271-297.
2. Smajilovic S, Hansen JL, Christoffersen TE et al. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 2006; 348: 1215-1223.
3. Ziegelstein RC, Xiong Y, He C et al. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 2006; 342: 153-163.
4. Alam MU, Kirton JP, Wilkinson FL et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81: 260-268.
5. Molostvov G, James S, Fletcher S et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007; 293: F946-F955.
6. Kifor O, Moore Jr FD, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606.
7. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336.
8. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004; 15: 2579-2587.
9. Ritter CS, Finch JL, Slatopolsky EA et al. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 2001; 60: 1737-1744.
10. Lewin E, Garfia B, Recio FL et al. Persistent downregulation of calciumsensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 2002; 13: 2110-2116.
11. Mendoza FJ, Lopez I, Canalejo R et al. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats. Am J Physiol Renal Physiol 2009; 296: F605-F613.
12. Mizobuchi M, Ogata H, Hatamura I et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 2007; 362: 11-16.
13. Ivanovski O, Nikolov IG, Joki N et al. The calcimimetic R-568 retards uremiaenhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE) mice. Atherosclerosis 2009; 205: 55-62.
14. Ciceri P, Elli F, Brenna I et al. The calcimimetic calindol prevents high phosphate-induced vascular calcification by upregulating matrix GLA protein. Nephron Exp Nephrol 2012; 122: 75-82.
15. Farzaneh-Far A, Proudfoot D, Weissberg PL et al. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-740.
16. Mendoza FJ, Martinez-Moreno J, Almaden Y et al. Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. Calcif Tissue Int 2011; 88: 169-178.
17. Zebboudj AF, Shin V, Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003; 90: 756-765.
18. Schlieper G, Westenfeld R, Kruger T et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22: 387-395.
19. Schurgers LJ, Barreto DV, Barreto FC et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010; 5: 568-575.
20. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
21. Henley C, Davis J, Miller G et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313.
22. Jung S, Querfeld U, Muller D et al. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens 2012; 30: 2182-2191.
23. Kim HJ, Kim H, Shin N et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol 2013; 14: 112.
24. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27: 784-790.
25. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116.
26. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-F1322.
27. Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017-2025.
28. Schoppet M, Hofbauer LC, Brinskelle-Schmal N et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 2012; 97: E575-E583.
29. Lindberg K, Olauson H, Amin R et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8: e60658.
30. Scialla JJ, Lau WL, Reilly MP et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168.
31. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
32. Koleganova N, Piecha G, Ritz E et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71.
33. Walter S, Baruch A, Dong J et al. Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 2013; 346: 229-240.
34. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589.
35. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
36. Palmer SC, Nistor I, Craig JC et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10: e1001436.
37. Raggi P, Chertow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
38. Chertow GM, Block GA, Correa-Rotter R et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.